-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q3 2016 to Q4 2024.
- Avalo Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending December 31, 2024 was 137 USD/shares, a 46.9% decline year-over-year.
- Avalo Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending December 31, 2024 was -20.9 USD/shares, a 81.6% increase year-over-year.
- Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2024 was -20.9 USD/shares, a 81.6% increase from 2023.
- Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -114 USD/shares.
- Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -1.06K USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)